Home / Drug shortages / Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension

Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension — FDA Drug Shortage

To Be Discontinued — Novo Nordisk, Inc.

The FDA lists a drug shortage record for Insulin Aspart Protamine and Insulin Aspart Mix 70/30 Injectable Suspension (injectable suspension) from Novo Nordisk, Inc. with status To Be Discontinued. The shortage was first posted on 07/21/2025.

Shortage Details

Status
To Be Discontinued
Company
Novo Nordisk, Inc.
Package NDC
73070-203-15
Dosage Form
Injectable Suspension
Presentation
Insulin Aspart Protamine and Insulin Aspart Mix 70/30, Injectable Suspension, 3 mL vial Insulin aspart protamine and insulin aspart Mix 70/30 FlexPen® (NDC 73070-203-15)
Initial Posting
07/21/2025
Revised Date

FDA data resources